Stock Update: AbbVie Inc (NYSE:ABBV) – U.S. FDA Grants Priority Review to AbbVie for Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Virus Patients with Compe

[PR Newswire] – NORTH CHICAGO, Ill., Jan. 7, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental … Read more on this. AbbVie Inc. (ABBV) , valued at $93.23B, started trading this morning at $56.54. Looking at today’s market, ABBV one day range is $56.34 to $57.06 with the price of the stock fluctuating between $45.45 to $71.60 over the last 52 weeks. Priced at 13.37x this year’s forecasted earnings, ABBV shares are relatively expensive compared to the industry’s -3.55x forward p/e ratio. And for passive income investors, the company pays shareholders $2.28 per share annually in dividends, yielding 3.85%. In a review of the consensus earnings estimate this quarter, 15 sell-side analysts are looking at $1.13 per share, which would be $0.24 better than the year-ago quarter and a $0.02 sequential decrease. In looking at the bigger picture, the full-year EPS estimate of $4.29 would be a $0.97 improvement when compared to the previous year’s annual results. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $6.41 Billion. If realized, that would be a 19.37% increase over the year-ago quarter. More recently, Morgan Stanley upgraded ABBV from Equal-Weight to Overweight (Nov 2, 2015). Previously, Citigroup upgraded ABBV from Sell to Neutral. When considering if the stock is under or overvalued, the average price target is $73.53, which is 30.05% above where the stock opened this morning. See more in (NYSE:ABBV) Similar Articles: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces FDA Acceptance of New Drug Application for a Once-Daily Formulation of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) to Treat Genotype 1 Chronic Hepatitis C Virus Infection Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C Market Update: AbbVie Inc (NYSE:ABBV) – AbbVie Demonstrates Commitment to Hepatitis C Patients with New Data on VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) and Ongoing Clinical Development Program at The Liver Meeting® 2015